Sleep disturbance in children with moderate/severe atopic dermatitis: A case-control study - 13/01/18
, Kelly Mueller b, Lacey Kruse, MD c, Peter Boor, MD c, Stephen Sheldon, MD d, Phyllis Zee, MD, PhD e, Amy S. Paller, MS, MD bAbstract |
Background |
Sleep is disturbed in 60% of children with atopic dermatitis (AD).
Objective |
To characterize sleep in a cohort of children with moderate-to-severe AD and determine methods for assessment of sleep disturbance.
Methods |
A case-control study compared children age 6 to 17 years who have moderate-to-severe AD with age- and sex-matched healthy controls. Participants wore actigraphy watches and completed sleep- and disease-specific questionnaires.
Results |
Nineteen patients with AD and 19 controls completed the study. The patients with AD experienced wake after sleep onset (WASO) for 103 plus or minus 55 minutes as compared with 50 plus or minus 27 minutes in the controls (P < .01). They had a higher frequency of restless sleep, daytime sleepiness, difficulty falling back to sleep at night, and teacher-reported daytime sleepiness. Disease severity correlated well with WASO (total SCORing Atopic Dermatitis score: r = 0.61, P < .01; objective SCORing Atopic Dermatitis score: r = 0.58, P = .01; and Eczema Area and Severity Index: r = 0.68, P < .01). The Children's Dermatology Life Quality Index sleep question correlated with WASO (r = 0.52, P = .03), but self-reported itch severity did not (r = 0.28, P = .30).
Limitations |
The study cohort was small.
Conclusion |
Children with moderate-to-severe AD experience more WASO and lower sleep efficiency than healthy controls but similar bedtime and wake time, sleep duration, and sleep onset latency.
Le texte complet de cet article est disponible en PDF.Key Words : actigraphy, atopic dermatitis, circadian, itch, nocturnal, scratch, screening, sleep, sleep disturbance, wake after sleep onset
Abbreviation used : AD, AR, CDLQI, EASI, PSQ, SCORAD, WASO
Plan
| Supported by the American College of Allergy, Asthma and Immunology Young Faculty Support Award (to AF) and by the Ann and Robert H. Lurie Children's Hospital of Chicago (to AF) and the Society for Pediatric Dermatology William Weston Grant (to LK and AP). This project was supported by grant K12HS023011 (to AF) from the Agency for Healthcare Research and Quality. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Agency for Healthcare Research and Quality. |
|
| Conflicts of interest: None declared. |
|
| Reprints not available from the authors. |
Vol 78 - N° 2
P. 336-341 - février 2018 Retour au numéro
Article précédent
- Commentary: The Corrona-National Psoriasis Foundation Psoriasis Registry : A new collaborative approach for postapproval registries
- Bruce Strober
- Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: A systematic review and meta-analysis
- François Chasset, Toufik Tounsi, Elise Cesbron, Annick Barbaud, Camille Francès, Laurent Arnaud
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?